Trial Profile
A Pilot, Open-Label, Dose Response Study Investigating the Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- 13 Oct 2020 Status changed from recruiting to discontinued.
- 26 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 26 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.